Lexaria Bioscience Corp. (NASDAQ: LEXX) announced that dosing has begun in its Animal Study #1 (GLP-1-A26-1) on June 10, 2026. The study evaluates formulation enhancements using DehydraTECH-semaglutide and DehydraTECH-CBD compositions to explore improved performance and establish new intellectual property claims. Results are expected by early September, barring interruptions.

The study utilizes Sprague-Dawley rats across 11 separate arms to quantify pharmacokinetic performance over an 8-24 hour post-dosing period. A key objective is to evaluate innovative alternative formulations to SNAC (salcaprozate sodium), currently used by Novo Nordisk in oral Rybelsus and Wegovy products. Lexaria has filed three new patent applications anticipating technological improvements in this area. The study will also measure drug concentrations in the brain, leveraging DehydraTECH's evidenced superior absorption into brain tissue.

Separately, Lexaria received its first Australian patent grant (#2023302884) in Family #21 for Pharmaceutical Compositions and Methods for Treating Hypertension on June 11, 2026. This is the company's 7th patent in this family, with a term until April 25, 2043. The company holds a robust intellectual property portfolio with 66 patents granted worldwide.

Study Design and Funding

The study includes one reference arm using an existing DHT-sema composition and another using an existing DHT-CBD composition. Lexaria will use proprietary historical data from these reference arms as baseline comparators. The study is fully funded from existing corporate resources.

Patent Portfolio Expansion

The recent Australian grant adds to Lexaria's global patent holdings. The company continues to pursue business development opportunities with commercial partners for its DehydraTECH technology, which aims to improve bio-absorption and reduce side effects.

Lexaria Bioscience Corp. has completed dosing in its 2026 Animal Study #2 (GLP-1-A26-2), evaluating formulation enhancements for two next-generation glucagon-like peptide-1 (GLP-1) drugs using its proprietary DehydraTECH technology. The study aims to explore potential improvements in drug delivery performance and stake new intellectual property claims. Dosing for the study was finalized on June 9, 2026, in Kelowna, BC.

The investigation focuses on retatrutide, owned by Eli Lilly and Company, and amycretin, owned by Novo Nordisk. Retatrutide is a triple hormone receptor agonist targeting GLP-1, glucagon, and GIP, currently administered via weekly injections. Lexaria's study examines oral dosing through tablets and capsules, comparing absorption primarily through the stomach or intestine.

Study Objectives and Methodology

The study comprises 18 different arms to evaluate novel DehydraTECH compositions. Blood samples are collected over a 24-hour post-dosing period to quantify pharmacokinetic (PK) performance. Primary goals include assessing compatibility with retatrutide and amycretin, centered on PK performance and tolerability.

Technology and Potential Benefits

DehydraTECH is Lexaria's patented drug delivery platform designed to improve oral drug bio-absorption and reduce side effects. The study evaluates alternative formulations to salcaprozate sodium (SNAC) technology used in Novo Nordisk's Rybelsus and Wegovy. Compositions include sodium caprate, a delivery enabling compound shown to influence gastrointestinal absorption.

Common side effects of GLP-1 drugs include nausea, diarrhea, and vomiting. Lexaria aims to demonstrate that DehydraTECH processing may lower the severity and frequency of these side effects while maintaining or improving efficacy.

Strategic Implications

Richard Christopher, CEO of Lexaria Bioscience, described the study as a watershed moment for the company's GLP-1 investigations. Success would expand DehydraTECH's applicability to triple-agonist weight-loss peptides in late-stage development, potentially dominating future markets. The study is fully self-sponsored and funded from existing corporate resources.